Berenberg Bank Keeps Their Buy Rating on Health Catalyst (HCAT)

Berenberg Bank analyst Dev Weerasuriya maintained a Buy rating on Health Catalyst (HCATResearch Report) today and set a price target of $17.00. The company’s shares closed yesterday at $6.47.

According to TipRanks, Weerasuriya is an analyst with an average return of -16.7% and a 31.03% success rate. Weerasuriya covers the Technology sector, focusing on stocks such as Omnicell, Health Catalyst, and Accolade.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Health Catalyst with a $15.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Health Catalyst’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $70.63 million and a GAAP net loss of $33.43 million. In comparison, last year the company earned a revenue of $59.63 million and had a GAAP net loss of $35.83 million

Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HCAT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in Salt Lake City, UT.

Read More on HCAT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More